Diabetes Case Reports

Abstrait

Role of GLP-1 analogues in cardiovascular

Nariman Fehmi

Diabetes prevalence is increasing at an exponential rate, hence are the problems of management and control. According to the International Diabetes Federation report in 2013, 382 Millions have diabetes and the number of people will rise beyond 592 million by 2035 with an increase of approximately 55%. Type2 Diabetes Mellitus (T2DM) associated with Obesity, Dyslipidemia and Hypertension. The latter, plays a major role in development of cardiovascular disease (CVD).It has been observed that the prevalence of hypertension is higher in people with T2DM than the general public. Macro vascular complications are still the primary cause of death in patients with T2DM.Glucagon like peptide-1 (GLP-1) receptor agonists are new class of anti-hyperglycemic agents having cardio protective effects, in the form of blood glucose control, weight loss, systolic blood pressure reduction and improvement of lipid profile. This research paper will discuss Types, mode of action (Incretin Effect ) and how do these hormones regulate glucose metabolism and landmark trials that showed effectiveness of different types of GLP-1 agonists the newer preparations to be effective when compared head to head or with other medications. How cost effective are GLP-1 analogues compared to other diabetic medications including insulin? And there potential role in cardiovascular disease. Finally, with increasing prevalence of diabetes the use of GLP-1 has been shown to reduce weight, systolic blood pressure and improve both lipid and glycemic profiles.